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Background and purpose — According to previous Nordic 
Arthroplasty Register Association (NARA) data, the 10-year 
implant survival of cemented total hip arthroplasties (THAs) is 
94% in patients aged 65–74 and 96% in patients aged 75 or more. 
Here we report a brand-level comparison of cemented THA based 
on the NARA database, which has not been done previously.
Patients and methods — We determined the rate of implant 
survival of the 9 most common cemented THAs in the NARA 
database. We used Kaplan-Meier analysis with 95% CI to study 
implant survival at 10 and 15 years, and Cox multiple regression 
to assess survival and hazard ratios (HRs), with revision for any 
reason as endpoint and with adjustment for age, sex, diagnosis, 
and femoral head material. 
Results — Spectron EF THA (89.9% (CI: 89.3–90.5)) and Elite 
THA (89.8% (CI: 89.0–90.6)) had the lowest 10-year survivor-
ship. Lubinus (95.7% survival, CI: 95.5–95.9), MS 30 (96.6%, 
CI: 95.8–97.4), and C-stem THA (95.8%, CI: 94.8–96.8) had a 
10-year survivorship of at least 95%. Lubinus (revision risk (RR) 
= 0.77, CI: 0.73–0.81), Müller (RR = 0.83, CI: 0.70–0.99), MS-30 
(RR = 0.73, CI: 0.63–0.86), C-stem (RR = 0.70, CI: 0.55–0.90), and 
Exeter Duration THA (RR = 0.84, CI: 0.77–0.90) had a lower risk 
of revision than Charnley THA, the reference implant.
Interpretation — The Spectron EF THA and the Elite THA had 
a lower implant survival than the Charnley, Exeter, and Lubinus 
THAs. Implant survival of the Müller, MS 30, CPT, and C-stem 
THAs was above the acceptable limit for 10-year survival.  
■
Cemented low-friction arthroplasty, pioneered by Sir John 
Charnley, is the basis of the modern total hip arthroplasty 
(THA). Charnley THA (DePuy; Johnson and Johnson, New 
Brunswick, NJ) is still considered to be the gold standard 
against which all other devices are compared (Warth et al. 
2014). The Lubinus THA (Waldemar Link, Hamburg, Ger-
many) and Exeter THA (Stryker Howmedica, Mahwah, New 
Jersey, US) are well-documented devices with tens of thou-
sands of implantations worldwide (SHAR 2014, NJR 2015). 
There are, however, several other less common cemented 
devices with limited data available on implant survival. 
The Nordic Arthroplasty Register Association (NARA) was 
established in 2007 in Sweden, Norway, and Denmark with 
the overall aim of improving the quality of joint replacement 
surgery by registry-based research collaboration. Finland 
became a member of NARA in 2010. The total population of 
the 4 countries is currently 26 million.
It has been stated, based on NARA data, that the survival 
of cemented implants for total hip replacement is higher 
than that of uncemented implants in patients aged 65 years 
or more (Mäkelä et al. 2014a). In younger patients, unce-
mented implants do not perform better regarding overall 
revision rate, but they have a lower long-term risk of revi-
sion due to aseptic loosening (Pedersen et al. 2014). In 
countrywise analyses, the differences in THA survival rates 
in different Nordic countries turned out to be consider-
able, with inferior overall results for cemented THAs in 
Finland. Implant survival of cemented THAs was higher in 
Sweden than in other Nordic countries (Mäkelä et al. 2014b).
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It is clear that brand-level implant survival data for cemented 
THA are required. We therefore determined the implant sur-
vival of the most common cemented THA brands in the Nordic 
countries based on the NARA database.
Patients and methods
Sources of data
The THA registries of Sweden, Denmark, Norway, and Fin-
land participated. From 1995 through 2013, all 4 registries 
used individual-based registration of THAs and patients. A 
minimal NARA dataset was created, containing data that all 
the registries could deliver (Havelin et al. 2009). The degree 
of coverage and completeness in the Nordic registries is high 
(Pedersen et al. 2004, Arthursson et al. 2005, Espehaug et al. 
2006, DHAR 2014, SHAR 2014, FAR 2015). Selection and 
transformation of the respective datasets and de-identifi cation 
of the patients, including deletion of the national civil regis-
tration numbers, was performed within each national registry. 
Anonymous data were then merged into a common database. 
Devices
360,584 primary all-cemented THAs were registered in 
the NARA database from 1995 through 2013. The 9 most 
common cemented THAs were assessed: Lubinus, Exeter, 
Charnley, Spectron (Smith and Nephew, Memphis, TN), 
MS-30 (Zimmer, Winterthur, Switzerland), CPT (Zimmer, 
Warsaw, IN), Elite (DePuy; Johnson and Johnson, New Bruns-
wick, NJ), Müller THA (Zimmer, Winterthur, Switzerland), 
and C-stem THA (DePuy, Johnson and Johnson, New Bruns-
wick, NJ) (Table 1). 
We assessed survivorship of implant families consisting of 
all versions of the device (see Table 2, Supplementary data), as 
several versions of the study implants were introduced during 
the study period. The different versions of the study implants 
were not necessarily the same in the 4 countries. Furthermore, 
the study devices were not necessarily coded similarly in the 
4 registries. Only those cup/stem combinations with at least 
100 implantations in a country were included. The cup/stem 
combinations assessed are listed in Table 2 (Supplementary 
data). Elite, MS 30, C-stem, CPT, and Müller THAs were cre-
ated by combining the study stem with a cemented acetabular 
component by the same manufacturer. 
Due to similar coding of the cup component in all 4 national 
registries, we had suffi cient numbers to perform separate anal-
yses of the Exeter X3 Rimfi t, Exeter Contemporary, Exeter 
All-poly, and Exeter Duration (Table 3). 
Statistics
We used Kaplan-Meier analysis with 95% confi dence intervals 
(CIs) to assess implant survival at 10 and 15 years, until there 
were at least 100 THRs left at risk. Patients were censored at 
death or December 31, 2013, whichever came fi rst. Outcome 
was revision for any reason, defi ned as removal or exchange of 
at least 1 of the components. Kaplan-Meier survivorship was 
also assessed separately for each device for 2 time periods, 
1995–2004 and 2005–2013, using any reason for revision as 
endpoint. Furthermore, Kaplan-Meier survivorship for aseptic 
loosening of the cup, stem, or both components was assessed 
depending on the type of cement used (Palacos-type, Simplex-
type, or other) (Espehaug et al. 2009). We used Cox multiple 
regression to determine survival rates and hazard ratios (HRs), 
with revision for any reason as endpoint, and with adjustment 
for age (< 60, 60–64, 65–69, 70–74, ≥ 75), sex, diagnosis (pri-
mary osteoarthritis, hip fracture, non-traumatic femoral head 
necrosis, infl ammatory disease, childhood hip disease, or 
other/unknown), and femoral head material (metal, ceramics, 
or other/unknown). The assumption of proportional hazards 
was fulfi lled, as evaluated by visual inspection of log-minus-
log-plots. 
Both Kaplan-Meier and Cox analysis are based on the 
assumption of non-informative censoring, an assumption that 
is not fulfi lled when estimating revision risk and censoring for 
death. Thus, competing risk assessment was also performed 
using Stata 14 statistical software, and these data are available 
in Table 8 (see Supplementary data).
Table 1. Number and proportion of study implants, and demo-
graphic data
  Propor-    Mean
  tion Mean Female POA follow-up
THA  n  % age %  %  years
Charnley 43,849 15 72 69 78 9.6
Lubinus 116,186 41 72 61 81 6.9
Exeter 75,880 26 72 64 84 7.0
Spectron EF 25,214 8.8 73 69 80 7.2
Müller 3,192 1.1 71 66 88 8.9
MS-30 8,674 3.0 71 64 89 4.3
CPT 6,222 2.2 73 66 85 8.8
Elite 5,647 2.0 70 66 74 10.1
C-stem 2,082 0.7 71 63 86 7.8
Total 286,946 100 72 64 82 7.4
POA: Primary osteoarthritis.
Table 3. Number and proportion of Exeter-subgroup devices, and 
demographic data
  Propor-   Primary Mean
  tion Mean Female OA follow-up
Exeter THA  n  % age %  %  years
X3 Rimfi t 7,189 9.5 73 65 84 1.4
Contemporary 19,889 26 74 67 85 6.1
All-poly 25,032 33 72 65 81 9.3
Duration 23,770 31 71 61 86 7.0
Total 75,880 100 72 64 83 7.0
OA: osteoarthritis.
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Patients with bilateral procedures were included, as earlier 
research has shown that this does not bias the results (Lie et 
al. 2004, Ranstam and Robertsson 2010). We considered any 
p-values less than 0.05 to be statistically signifi cant. For most 
statistical analyses, we used SPSS version 22.0.
Ethics
Ethical approval of the study was obtained through each 
national registry.
 
Results
The Lubinus THA was the most common study device, being 
used in 41% of all implantations. Mean age at the time of sur-
gery was highest for the CPT THA (73 years). The propor-
tion of female patients was highest for Charnley THA (69%) 
(Tables 1 and 3, and Figure 1).  
Several THAs had a 10-year survivorship of 95% or more, 
including Lubinus (95.7%, CI: 95.5–95.9), MS 30 (96.6%, CI: 
95.8–97.4), and C-stem (95.8%, CI: 94.8–96.8). The lowest 
10-year implant survival was observed in patients with Spec-
tron EF THA (89.9%, CI: 89.3–90.5) and Elite THA (89.8%, 
CI: 89.0–90.6) (Tables 4 and 5, and Figures 2 and 3).
Implant survival of Charnley, Exeter, and Elite THAs 
with Palacos-type cement was higher than those of the same 
devices with other types of cement. Implant survival of Lubi-
nus, Spectron, and Müller THAs with Palacos- and Simplex-
type cement was higher than those of the same devices with 
other types of cement (Table 6).
Lubinus (revision risk (RR) = 0.77, CI: 0.73–0.81), Müller 
(RR = 0.83, CI: 0.70–0.99), MS 30 (RR = 0.73, CI: 0.63–
0.86), and C-stem THAs (RR = 0.70, CI: 0.55–0.90) had a 
lower revision risk than Charnley THA. Spectron EF (RR= 
1.73, CI: 1.62–1.84), Exeter (RR = 1.25, CI: 1.18–1.31), and 
Elite THAs (RR = 1.65, CI: 1.51–1.80) had a higher revision 
risk than Charnley THA after adjusting for age, sex, and diag-
nosis (Table 4).
In subgroup analysis of the Exeter devices, the Exeter X3 
Rimfi t THA had a similar revision risk to that of the reference 
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Figure 1. Time trends in using the study devices during the period 
1995–2013.
Table 4. Kaplan-Meier survivorship of the study devices at 10 and 15 years with revision for any reason as the 
endpoint, and adjusted revision rate (RR) (age, sex, diagnosis, femoral head material) for revision using Cox 
regression
 At risk at  10-year survival  At risk at  15-year survival  Adjusted RR
THA 10 years  (95% CI), % 15 years (95% CI), % (95% CI), % p-value
Charnley  21,794 94.1 (93.9–94.3) 7,199 90.7 (90.3–91.1) 1.0  -
Lubinus  29,016 95.7 (95.5–95.9) 6,685 92.4 (92.0–92.8) 0.77 (0.73–0.81) < 0.001
Exeter 19,606 93.5 (93.3–93.7) 4,066 86.0 (85.4–86.6) 1.25 (1.18–1.31) < 0.001
Spectron EF  5,311 89.9 (89.3–90.5) 512 79.8 (78.2–81.4) 1.73 (1.62–1.84) < 0.001
Müller  1,225 94.9 (93.9–95.9) 372 92.6 (91.2–94.0) 0.83 (0.70–0.99) 0.03
MS-30  834 96.6 (95.8–97.4) - - 0.73 (0.63–0.86) < 0.001
CPT  2,756 94.9 (94.3–95.5) 391 91.6 (90.4–92.8) 0.94 (0.84–1.06) 0.3
Elite  3,201 89.8 (89.0–90.6) 986 83.9 (82.5–85.3) 1.65 (1.51–1.80) < 0.001
C-stem  550 95.8 (94.8–96.8) - - 0.70 (0.55–0.90) 0.005
Table 5. Implant survival at 7 years for the time periods 1995–2004 
and 2005–2013, with any reason for revision as the endpoint
  7-year survival  7-year survival
  for 1995–2004   for 2005–2013
THA At risk   (95% CI), % At risk  (95% CI), %
Charnley 27,686 95.7 (95.5–95.9) 1,953 95.7 (95.1–96.3)
Lubinus 40,948 97.1 (96.9–97.3) 11,662 96.9 (96.7–97.1)
Exeter 27,748 95.8 (95.6–96.0) 7,411 96.1 (95.9–96.3)
Spectron 8,783 95.2 (94.8–95.6) 4,000 95.1 (94.7–95.5)
Müller 1,656 96.6 (95.8–97.4) 437 95.9 (94.5–97.3)
MS-30 1,005 97.3 (96.3–98.3) 493 97.5 (96.9–98.1)
CPT 3,609 96.6 (96.0–97.2) 719 95.1 (93.7–96.5)
Elite 3,959 92.7 (91.9–93.5) 13 -
C-stem 929 97.5 (96.5–98.5) 496 96.4 (95.0–97.8)
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implant (Charnley) THA (RR = 1.13, CI: 0.91–1.39). The 
Exeter Duration THA had a lower revision risk than the refer-
ence implant (RR = 0.84, CI: 0.77–0.90) (Table 7).
Results of the competing risk assessments are given in Table 
8 (see Supplementary data). The results varied slightly, but 
they did not change the ranking of the implants.  
Discussion
The Spectron EF and Elite THAs had a lower implant survival 
than the Charnley THA, the reference implant. Implant sur-
vival of Müller, MS 30, CPT, and C-stem THAs (94.9–96.6% 
at 10 years) was far above the acceptable limit for 10-year 
survival. However, the total amount of these devices was small 
compared to Charnley, Lubinus, and Exeter THAs, although 
all of them had been implanted in more than 2,000 hips. When 
an implant becomes more common and is used by an increas-
ing number of surgeons, the results will be more representa-
tive since they can be assumed to refl ect a wider range of dif-
ferences in surgical technique.       
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Figure 2. Kaplan-Meier implant survival. Green lines are upper and lower 95% confi dence limits.
Table 6. Kaplan-Meier survivorship of the study devices with either 
Palacos-type, Simplex-type, or other bone cement at 10 years with 
aseptic loosening as the endpoint
  At risk at 10-year survival
THA n 10 years (95% CI), %
Charnley + Palacos 38,925 18,950 97.2 (97.0–97.4)
Charnley + Simplex 411 242 92.4 (89.5–95.3)
Charnley + other 4,335 2,542 91.7 (90.7–92.7)
Lubinus + Palacos 93,393 24,918 98.1 (97.9–98.3)
Lubinus + Simplex 2,430 1,483 97.4 (96.6–98.2)
Lubinus + other 20,224 2,724 95.6 (95.0–96.2)
Exeter + Palacos 51,729 12,200 97.2 (97.0–97.4)
Exeter + Simplex 13,366 4,148 96.2 (95.8–96.6)
Exeter + other 10,310 3,057 96.1 (95.5–96.7)
Spectron + Palacos 22,152 5,031 92.6 (92.0–93.2)
Spectron + Simplex 1,523 144 92.8 (90.1–95.5)
Spectron + other 1,497 141 85.0 (80.5–89.5)
Müller + Palacos 2,108 888 97.7 (96.9–98.5)
Müller + Simplex 234 140 97.9 (95.5–100)
Müller + other 850 233 92.9 (90.5–95.3)
MS-30 + Palacos 4,250 898 98.8 (98.2–99.4)
CPT + Palacos 5,630 2,610 98.7 (98.3–99.1)
CPT + other 469 116 97.3 (94.8–99.8)
Elite + Palacos 4,222 2,450 94.4 (93.6–95.2)
Elite + Simplex 166 98 87.8 (82.5–93.1)
Elite + other 1,254 668 88.2 (86.2–90.2)
C-stem + Palacos 1,599 683 99.0 (98.4–99.6)
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A major strength of the present study was the unique col-
laboration of the 4 national registries to create a multinational 
database with large numbers of patients and a long follow-up 
time. The main weakness of the study was that we were unable 
to assess every updated version of each device separately. The 
study devices were implant families, consisting of several ver-
sions of the device. Another weakness was that we were not 
able to assess cup and stem survival separately with revision 
for any reason as the endpoint. These data are were not avail-
able from the Finnish Arthroplasty Register, and they were 
therefore not included in the 4-country minimal dataset either. 
Furthermore, our data did not include information on param-
eters such as surgeon volume, hospital volume, ASA grade, 
or preoperative patient-reported outcome measures (PROMs).
Implant survival of Charnley THAs was high (94.1% at 10 
years), but slightly lower than that reported by the NJR (10-
year survival of 95.1% for Charnley Ogee/Charnley and 97.0% 
for Charnley/Charnley) (NJR 2015). In Australia, 10-year sur-
vival for Charnley Ogee/Charnley was 91.6%, whereas that 
for Charnley/Charnley was 93.0% (AOANJRR 2015). The 
total amount of Charnley THAs in Australia was low (1,300), 
which might explain the slightly inferior results compared to 
ours. The Charnley THAs studied consisted of several ver-
sions of the Charnley stem, such as Charnley fl anged, Charn-
ley fl anged heavy, and Charnley fl at and round-backed stems. 
It has been stated previously that the implant survival of the 
Charnley THA after 1995 has been good, and differences in 
implant survival between Charnley stems are minor (Espe-
haug et al. 2009). Similarly, the cup designs of the Charnley 
THA that were assessed varied. The use of Charnley THAs 
decreased drastically towards the end of the study period. 
The Elite Plus THA was introduced in 1994 as the second 
modular evolution of the original Charnley THA. Several 
changes were made to the shape and the dimensions of the 
femoral component, to improve proximal load transfer and 
reduce contact stresses. The design also incorporated an under-
cutting of the neck fl ange (DePuy 1993). Overall survivorship 
of Elite THAs in our study was inferior to that of the refer-
ence implant. The Elite Plus stem has been withdrawn from 
the market due to divergent clinical results (Hauptfl eisch et al. 
2006, Kim et al. 2007, von Schewelov et al. 2010). Our results 
support these earlier fi ndings. A weakness of our Charnley 
vs. Elite THA analysis was that Elite cups were sometimes—
although rarely—used with Charnley stems, and vice versa, 
which may have biased our results. 
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Figure 3. Implant survival of THAs for the time periods 1995–2004 and 2005–2013, with revision for any reason as the endpoint
Table 7. Adjusted revision risk (age, sex, diagnosis, femoral head 
material) for revision of the Exeter-subgroup devices
THA Adjusted revision risk (95% CI) p-value
Charnley 1.0  -
Exeter X3 Rimfi t/Exeter 1.13 (0.91–1.39) 0.3
Exeter Contemporary/Exeter 1.41 (1.31–1.52) < 0.001
Exeter All-poly/Exeter 1.47 (1.39–1.56) < 0.001
Exeter Duration/Exeter 0.84 (0.77–0.90) < 0.001
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Implant survival of the third DePuy device assessed, the 
C-stem THA (95.8% at 10 years), was higher than that of the 
Charnley THA, and comparable to previous reports (a 10-year 
survival of 94.6% for C-stem/Elite Plus in the AOANJRR, and 
a10-year survival of 98% for C-stem/Elite Plus Ogee in the 
NJR). The triple-tapered, polished cemented C-stem intro-
duced in 1993 was based on the original Charnley concept of 
the fl at-back polished stem (Purbach et al. 2013). However, 
the total number of C-stem THAs that have been implanted 
to date in the Nordic countries—and also worldwide—is low 
compared to the original Charnley THA. 
Long-term survival of the Lubinus THA in our study was 
higher than that of the reference implant. Most of the study 
stems were SP II models (see Appendix) with a high degree 
of documentation (Annaratone et al. 2000, Wierer et al. 2013, 
Prins et al. 2014, SHAR 2014). However, most of the Lubinus 
THAs (79%) in our study were performed in Sweden, which 
has twice the population of each of the 3 other countries. In 
general, the implant survival of cemented THAs in Sweden 
is substantially higher than in the other 3 countries (Mäkelä 
et al. 2014). The Swedish Hip Arthroplasty Register has pro-
vided feedback to the profession and also continued training 
in cementing techniques for more than 30 years. So the excel-
lent implant survival of Lubinus THA in the present study may 
have been biased by the “Swedish factor”. The threshold for 
performing a revision operation is also culture-dependent, and 
may vary between the Nordic countries. X-linked Lubinus 
cups were coded separately in the NARA hip database only 
in Sweden, so we did not assess X-linked Lubinus THA sepa-
rately. However, these devices will be able to be detected in 
the future using NARA data, when the catalog number-based 
register is ready.
We found that long-term survival of Exeter THAs was sat-
isfactory, although inferior to that of the reference device. The 
overall implant survival of Exeter THAs in our study (93.5%) 
was slightly lower than that reported by the NJR (10-year sur-
vival of 97.1% for Exeter V40/Contemporary, and 96.3% for 
Exeter V40/Exeter Duration), but similar to that reported by 
the AOANJRR (10-year survival for Exeter V40/Contempo-
rary of 94.1%). In the current study, the Exeter THA family 
consisted almost exclusively of Exeter Universal stems. The 
Exeter V40 stem was separately coded only in Denmark in 
the current NARA database, so the number of defi nite Exeter 
V40 THAs in the current study was low. However, we were 
able to do subgroup analyses for Exeter THAs according to 
the acetabular component (Table 6). The Exeter X3 Rimfi t 
THA (X3-stabilized UHMWPE, the latest version of high 
crosslinking) was coded separately in each of the 4 registries. 
Implant survival of this device was comparable to that of 
the reference implant. The total number of Exeter X3 Rimfi t 
THAs was, however, small compared to Exeter Contem-
porary THAs and Exeter All-poly THAs, and the follow-up 
time was shorter. Contemporary cups are made of Duration-
stabilized UHMWPE, whereas all-polyethylene cups are not 
Duration-stabilized. Duration-stabilized UHMWPE was the 
fi rst annealed (heated below melting temperature) moder-
ately crosslinked polyethylene with 3 Mrad of irradiation. The 
long-term implant survival of Exeter Contemporary THAs and 
Exeter All-poly THAs was good, although not quite as good as 
that of the best performers. Based on previous Swedish data, 
the implant survival of Lubinus THAs and Exeter THAs is 
similar in Sweden (SHAR 2014). The “Sweden factor” appears 
to have a major impact on the survival of the Exeter THA also. 
The most common Swedish device was the Exeter Duration 
THA, with excellent survivorship. The Exeter Duration THA 
was named specifi cally in Sweden and Denmark only and we 
did not ask for subclassifi cation in the other countries for this 
particular study. In England and Wales, implant survival of 
Exeter/Contemporary THA was slightly higher than that of 
Exeter/Exeter Duration THA, which was contrary to our fi nd-
ings. In Australia, Exeter/Duration THA is not assessed sepa-
rately. However, 15-year survivorship of the Exeter THA in 
our study was inferior to that of the best performers. 15-year 
survival data for the Exeter THA are not yet available from the 
NJR or the AOANJRR. 
It should be taken into account that the Exeter stem is very 
easy to revise, and the revision method of cementing a new 
smaller stem without removing the old bone cement is well 
established (te Stroet et al. 2014). The ease of the Exeter stem 
revision could have biased survivorship of the Exeter THA 
in our study. However, the revision risk of the Exeter stem 
regarding periprosthetic fracture is higher than for the Lubinus 
SP II stem (Thien et al. 2014). 
Implant survival of Spectron EF THAs in our study (89.9% 
at 10 years, and 79.8% at 15 years) was inferior to that of 
other THAs, and also inferior compared to previous reports 
(with a 10-year survival of 92.1% for Spectron EF/Refl ec-
tion in the AOANJRR and in Norway (Espehaug et al. 2009)). 
Spectron THA in our study consisted mostly of Spectron EF 
stems and Refl ection cups. It has been shown in RSA stud-
ies that cups with ethylene oxide-sterilized polyethylene (such 
as the Refl ection cup) have higher wear rates than those with 
gamma irradiation-sterilized polyethylene (Digas 2005, Kadar 
et al. 2011a, Jonsson et al. 2015). The modular Spectron EF 
stem was introduced in 1988, and in 1989 the roughness of 
the proximal part of the stem was increased. 5 years later, 
further modifi cations to the stem were introduced and the 
name was altered to Spectron EF Primary. The collar became 
polished and smaller sizes were introduced. This design per-
formed worse than its predecessor, especially the smallest 
sizes (, Thien and Kärrholm 2010, SHAR 2014). It has been 
suggested that the addition of a rough surface to the Spec-
tron stem has been detrimental to the long-term success of the 
prosthesis (Gonzalez Della Valle et al. 2006, Grose et al. 2006, 
Espehaug et al. 2009, Kadar et al. 2011b). Our results support 
these fi ndings.
Implant survival of Müller THAs (94.9% at 10 years, and 
92.6% at 15 years) was higher than that of the reference 
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implant, and comparable to that in previous reports (Mäkelä et 
al. 2008, Clauss et al. 2013, Nikolaou et al. 2013). The Müller 
THAs studied consisted mostly of Müller straight stems and of 
Müller all-polyethylene cups. Müller stems made of titanium 
alloy with a roughened surface fi nish were excluded due to pre-
vious reports of increased revision risk compared to polished 
cobalt-chrome Müller stems (Clauss et al. 2013, FAR 2015). 
Implant survival of another Zimmer device, the MS-30 THA 
(96.6% at 10 years) was also high, and comparable to those 
of previous reports (10-year survival of 97.5% for MS-30/
Low Profi le in the AOANJRR, and 10-year survival of 99% 
for MS-30/Low Profi le in the NJR). However, stem survival as 
poor as 80% at 12 years has also been reported for the MS-30 
(Witte et al. 2009). The original MS-30 (Morscher-Sportorno) 
stem was made of stainless steel, and was straight, three-
dimensionally tapered, collarless, and matt-surfaced (Berli et 
al. 2005, Brigstocke et al. 2014). However, most MS-30 stems 
inserted in Sweden have been polished. The MS-30 stem was 
used in combination with Zimmer all-polyethylene cups such 
as the ZCA and highly crosslinked ZCA XLPE. A weakness 
of the Müller and MS-30 THA analysis was that all the Müller 
THAs studied were performed in Finland and in Sweden, and 
all the MS-30 THAs were performed in Sweden and Norway. 
Implant survival of the third Zimmer device studied, the 
CPT THA (94.9% at 10 years, and 91.6% at 15 years), was 
comparable to that of the reference THA, and to those in pre-
vious reports (a 10-year survival of 95.4% for CPT/ZCA in 
the AOANJRR, and a 10-year survival of 96.4% for CPT/ZCA 
in the NJR). The CPT (collarless polished tapered) stem was 
originally developed as a collarless, highly polished, double-
tapered prosthesis for distribution in the USA. Like the Exeter 
stem, from which the principles of its design were taken, the 
CPT also uses the taper slip concept. The CPT differs from 
the Exeter Universal stem in its broad lateral shoulder, more 
complete lateral taper, and more rectangular proximal geom-
etry (Burston et al. 2012). CPT stems made of stainless steel 
and made of chromium cobalt were included in the current 
study, which may have caused bias. Although performed in all 
4 countries, the total number of CPT THAs was small. 
The long-term performance of cemented THAs depends 
on many factors in addition to the implant, such as the char-
acteristics of the patient, surgical and cementing technique, 
and the properties of the bone cement used. Although all bone 
cements used today are based on methylmethacrylate, their 
performance may vary. Poor results have been found for some 
low-viscosity cements (Havelin et al. 1995, Furnes et al. 1997, 
Espehaug et al. 2002). We therefore also determined implant 
survival according to the type of cement used (Palacos-type, 
Simplex-type, or other) (Espehaug 2009).  Implant survival 
of Charnley, Elite, and Exeter THAs was higher when used 
with high-viscosity, Palacos-type cement. Our results support 
previous fi ndings (Havelin et al. 1995, Espehaug et al. 2002). 
Implant survival of the study devices was similar in the period 
1995–2004 and the period 2005–2013. Cementing techniques 
appear to have become standardized in the Nordic countries 
over the last 2 decades. 
In summary, several cemented THA brands perform well in 
the long term. However, there are substantial differences in 
implant survival between high and low performers. 
Supplementary data
Tables 2 and 8 are available on the Acta Orthopaedica website 
att www.orthop.org, number 10004.
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